Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Abstract

PurposeThis retrospective study presents a comparative analysis of the overall survival and toxicities, as side effects, of docetaxel plus cyclophosphamide (TC) and doxorubicin plus cyclophosphamide (AC). The study measured their efficacies during adjuvant chemotherapy, treating Pakistani breast cancer patients by validating the results obtained, with the published analysis of the same treatment given to US patients.Patients and methodsBetween June 2015 and September 2017, for four chemotherapy cycles, 189 patients out of 358 received TC (75 mg/m2 of docetaxel, 600 mg/m2 of cyclophosphamide) and 169 were treated with AC (60 mg/m2 of doxorubicin, 600 mg/m2 of cyclophosphamide). On the basis of using pathological markers to assess patients, toxicities, as side effects, (due to docetaxel, doxorubicin, and cyclophosphamide) were listed in the database of this study. Common factors with respect to common terminology criteria for adverse events version 5.0 and side effects listed in MedlinePlus, NIH US database, and from the database of this study were then separated to be included in comparison for this study. Statistically, chi-squared test was used at α=0.05.ResultsThere was no statistically significant difference between the proportions of patients with vomiting, extreme tiredness, diarrhea, mild anemia, stability, and overall survival because P-value >0.05. However, AC remained less toxic (P-value <0.05) by 22.6%, 25.7%, 25.3%, 12.4%, 20.8%, and 16.4% compared to TC for changes in taste, muscle pain, burning hands, change in hemoglobin level, moderate anemia, and needing blood transfusion respectively, whereas TC remained less toxic by 52.9%, 32.5%, and 26.3% for dizziness, weight loss, and sores in throat and mouth, respectively.ConclusionAt 27 months, TC was more toxic than AC, whereas both combinations had the same overall survival rate.

Computer Simulation Modeling for Analyzing Mammary Gland Tumor Cells Aggression Level Restricted by Comparative Chemotherapy using Docetaxel and Doxorubicin Both with Cyclophosphamide

“…Therefore, to validate the results of this study "overall trend of change in Hb level" and "overall trend of change in WBC count" of SMTA and rat models were compared with each other. "Overall trend of change in Hb level" was compared with the validated and published results (Adeel et al, 2019). It was observed that statistically (applying paired t-test) there was no significant difference between means of "overall trend of change in Hb level" observed form SMTA and rat models because p-value = 0.795>0.05.…”

“…This study is carried out for two combinations of chemotherapy including TC and AC, as discussed in our earlier work (Adeel et al, 2019). To calculate "overall trend of change in WBC count", Equation 2 was derived on the basis of a reported equation (Equation 1) (Adeel et al, 2019). Equation 1 was used to calculate "overall trend of change in Hb level".…”

“…For the selection of suitable medicine for any patient, oncologists take the decision by their experience and seeing patient's history, tumor grade and stage. In the present study, mammary gland tumor was induced in rat models followed by treatment with TC and AC which are widely used against breast cancer patients in hospitals of our region (Adeel et al, 2019). Using agent-based computer simulation and modeling technique, this study presents a simulation model for TC and AC.…”

“…Since SMTA was executed by providing the same drugs administration by which tumor-induced rat models were treated, so some results from SMTA and some results obtained from rat models were compared to validate the presented simulation model. For complete validation of the remaining SMTA results (that could not be obtained from rat models) were compared with published results (Adeel et al, 2019). This model, during its execution, analyzes the visual interactions of the mammary gland tumor cells aggression level, drugs administration, WBC count and Hb level affected by AC and TC.…”

“…The overall trend in subjects' Hb change, denoted by otHbc was calculated by already derived equation (Adeel et al, 2019):…”